目次

Table of Content

1. Research Methodology

2. Introduction To Menin Inhibitors
2.1 Background and Clinical Evolution
2.2 Advancements In Clinical Development

3. Clinical Relevance and Impact Of Menin Inhibitors

4. Menin Inhibitors Mechanism Of Action
4.1 Overview
4.2 Mechanistic Insights Of Some Novel Menin Inhibitors

5. Menin Inhibitors Application and Clinical Trials By Indication
5.1 Hematological Cancers
5.2 Solid Cancers
5.3 Diabetes

6. Revuforj (Revumenib ) First Approved Menin Inhibitor Drug
6.1 Overview and Patent Insight
6.2 Pricing and Dosing
6.3 Sales Insight

7. Global Menin Inhibitors Market Landscape
7.1 Current Market Scenario
7.2 Future Clinical and Commercialization Opportunities

8. Menin Inhibitors Clinical Research Innovation Trends By Region
8.1 US
8.2 Europe
8.3 Rest Of World

9. Menin Inhibitors Development Technologies Platforms By Companies
9.1 FUSIONandtrade; System - Biomea Fusion
9.2 Innovation Platform - Rongchang Pharmaceuticals
9.3 Next-generation Approach - CHARM Therapeutics
9.4 Proprietary Approach - Eilean Therapeutics

10. Global Menin Inhibitor Market Dynamics
10.1 Drivers and Opportunities
10.2 Challenges and Restraints

11. Global Menin Inhibitors Drugs Clinical Trials Overview
11.1 By Company
11.2 By Country
11.3 By Indication
11.4 By Phase

12. Global Menin Inhibitors Drugs Clinical Trials By Company, Indication and Phase
12.1 Preclinical
12.2 Phase-I
12.3 Phase-I/II
12.4 Phase-II
12.5 Phase-III
12.6 Preregistration

13. Marketed Menin Inhibitors Drugs Clinical Trials By Company, Indication and Phase

14. Competitive Landscape
14.1 Beyang Therapeutics
14.2 Biomea Fusion
14.3 BioNova Pharmaceuticals
14.4 Daiichi Sankyo Company
14.5 Easton Biopharmaceuticals
14.6 Eilean Therapeutics
14.7 HitGen
14.8 Janssen Research and Development
14.9 Rongchang Pharmaceuticals
14.10 Sumitomo Pharma

List of Figures & Tables
Figure 2-1: MEN1 Gene and Menin Protein Function In Cell Cycle Regulation and Tumor Suppression
Figure 2-2: Mechanism Of Menin Inhibition In Leukemia Cells
Figure 2-3: Historical Timeline Of MEN1 Discovery and Research
Figure 2-4: Role Of Menin In Oncogenesis and Action Of Menin Inhibitors
Figure 4-1: Revumenib - Mechanism Of Action In KMT2A-Rearranged AML
Figure 4-2: Revumenib - Mechanism Of Action In NPM1-Mutant AML
Figure 4-3: Ziftomenib - Mechanism Of Action In Menin-KMT2A Pathway
Figure 4-4: Icovamenib - Mechanism Of Action In Leukemia
Figure 4-5: Icovamenib - Mechanism Of Action In Type 2 Diabetes Mellitus
Figure 5-1: Menin In Leukemia: A Paradoxical Oncogenic Co-Factor
Figure 5-2: AUGMENT-101 Phase I/II (NCT04065399) Study - Initiation and Completion Years
Figure 5-3: EVOLVE-2 Phase III (NCT06652438) Study - Initiation and Completion Years
Figure 5-4: NCI-2024-00534 Phase II (NCT06229912) Study - Initiation and Completion Years
Figure 5-5: NCI-2023-00503 Phase II (NCT05761171) Study - Initiation and Completion Years
Figure 5-6: KOMET-001 Phase I/II (NCT04067336) Study - Initiation and Completion Years
Figure 5-7: KOMET-007 Phase I (NCT05735184) Study - Initiation and Completion Years
Figure 5-8: KOMET-001 Phase I/II (NCT04067336) Study - Initiation and Completion Years
Figure 5-9: KOMET-008 Phase I (NCT06001788) Study - Initiation and Completion Years
Figure 5-10: cAMeLot-2 Phase III (NCT06852222) Study - Initiation and Completion Years
Figure 5-11: KO-MEN-015 Phase I (NCT06655246) Study - Initiation and Completion Years
Figure 5-12: Menin - Role in andbeta;-Cell Dynamics and Diabetes
Figure 5-13: Diabetes - Menin Inhibition
Figure 6-1: Revuforj - Cost Per Unit and Supply (US$), July’2025
Figure 6-2: Revuforj - Global Annual Sales (US$ Million), 2024-2025
Figure 6-3: Revuforj - Global Quarterly Sales (US$ Million), Q1 and Q2’2025
Figure 6-4: Revuforj - Global Quarterly Sales (US$ Million), Q4’2024
Figure 7-1: Global - Menin Inhibitor Drug Market (US$ Million), 2024 -2025
Figure 7-2: BAML-16-001 Phase I/II (NCT03013998) Study - Initiation and Completion Years
Figure 7-3: Global - Menin Inhibitor Drug Market (US$ Million), 2026 - 2028
Figure 7-4: Menin Inhibitor Market - Future Opportunities
Figure 9-1: FUSIONandtrade; System - Biomea Fusion
Figure 9-2: Innovation Platform - Rongchang Pharmaceuticals
Figure 9-3: DragonFold Platform - Development Candidate Highlights
Figure 9-4: Proprietary Approach - Eilean Therapeutics
Figure 10-1: Global Menin Inhibitor Market - Drivers and Opportunities
Figure 10-2: Global Menin Inhibitor Market - Key challenges and Strategic Solutions
Figure 11-1: Global - Menin Inhibitor Drugs Clinical Trials by Company (Numbers), 2025 Till 2028
Figure 11-2: Global - Menin Inhibitor Drugs Clinical Trials by Country (Numbers), 2025 Till 2028
Figure 11-3: Global - Menin Inhibitor Drugs Clinical Trials by Indication (Numbers), 2025 Till 2028
Figure 11-4: Global - Menin Inhibitor Drugs Clinical Trials by Phase (Numbers), 2025 Till 2028
Table 5-1: Genetic Mutations In AML and Their Clinical Relevance
Table 6-1: Revuforj - Recommended Management and Dosage Modifications for Adverse Reactions
Table 6-2: Revuforj - Dosage Reduction For Adverse Reactions In Patients Not On Strong CYP3A4 Inhibitors
Table 6-3: Revuforj - Dosage Reduction for Adverse Reactions in Patients on Strong CYP3A4 Inhibitors
Table 6-4: Revuforj - Recommended Reduced Dosage Using Tablets for Patients Weighing Less than 40 kg